# A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

> **NCT06241599** · PHASE2,PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 300 (estimated)

## Conditions studied

- Recurrent or Metastatic Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** GP/PFLL+AK104
- **DRUG:** GP/PFLL+placebo

## Key facts

- **NCT ID:** NCT06241599
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06241599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06241599, "A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06241599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*